QUANTUM X LABS INC. current report, 13 November 2025

Business Context and Reporting Period

This Form 8-K is filed by Viewbix Inc. (not Quantum X Labs Inc., which is the target of the transaction) on November 13, 2025. The filing reports a material event under Item 8.01 regarding a strategic transaction to acquire Quantum X Labs Ltd., an Israeli company specializing in quantum computing and AI.

Key Financial Metrics

The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Viewbix Inc. or Quantum X Labs Ltd. The document focuses exclusively on the terms of a proposed acquisition.

Material Changes and Transaction Terms

On November 13, 2025, Viewbix Inc. entered into a new non-binding term sheet to acquire 100% of Quantum X Labs Ltd.'s issued and outstanding share capital. The key terms include:

  • Consideration: Viewbix will issue securities representing 40.0% of its post-closing issued and outstanding capital stock.
  • Structure: The consideration consists of:
    • Exchange Shares: Common stock representing 19.99% of post-closing capital (including shares from a concurrent Private Placement Offering).
    • Exchange Pre-Funded Warrants: Warrants representing the balance of the 40.0% allocation.
  • Earn-Out Provisions: Additional securities ("Earn Out Securities") may be issued up to a total aggregate of 65.0% of post-closing capital based on milestones:
    • 6%: Upon completion of the first prototype phase and a binding collaboration or patent filing within 18 months.
    • 8%: Upon completion of the second prototype phase and technical validation or additional patent filing within 30 months.
    • 11%: Upon reaching beta testing with partners or filing an additional patent within 36 months.

Guidance, Risks, and Contingencies

The transaction is subject to several material contingencies and risks:

  • Closing Conditions: Completion requires final due diligence, execution of definitive agreements, regulatory approvals, and stockholder approval in accordance with Nasdaq rules.
  • Forward-Looking Statements: The filing explicitly warns that the transaction is not guaranteed and may not occur due to factors beyond the company's control.
  • Non-Binding Nature: The current agreement is a non-binding term sheet; definitive agreements have not yet been executed.

Investor Verification Checklist

  • Verify the exact number of shares currently outstanding for Viewbix Inc. to calculate the dilution impact of the 40.0% initial issuance and potential 65.0% earn-out.
  • Confirm the status of the "Private Placement Offering" mentioned as part of the Exchange Shares calculation.
  • Monitor the execution of definitive agreements and the timeline for stockholder approval.
  • Assess the technical feasibility of Quantum X Labs' milestones (prototype phases, patent filings) given the high dilution risk associated with the earn-out.
  • Review the company's cash position to determine if it can sustain operations while awaiting transaction closure.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.